In a recent post on the IVI-sponsored Health Affairs featured blog series, Max Bronstein, Emil Kakkis, David Fajgenbaum, and Chip Chambers address the current landscape of drug development, making the case for the OPEN ACT (Orphan Product Extensions Now, Accelerating Cures and Treatments), new legislation that would extend the exclusivity period for any drug repurposed for a rare disease indication. The authors directly address critics of the legislation, arguing that the law would streamline the development of treatments for rare disease.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
